Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Petrelintide in renal impairment
NCT07076030Phase 1Completed
- Sponsor
- Zealand Pharma
- Start
- Apr 2025
- Primary completion
- Nov 2025
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of petrelintide in obesity (4 arms), sponsored by Zealand Pharma. Primary endpoint: Area Under the Plasma Concentration-Time Curve from Time 0 to Infinity. Started Apr 2025; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07076030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076030.